CRISPR RNA-guidedFokI nuclease and CRISPR/Cas9-directed gene trapping have also been used for the targeted disruption ofBCR-ABL in K562 cells (a human CML-derived cell line) [23,24]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.